As the $420B Cold Chain Booms, Ergodyne Arms the Front Lines
St. Paul, MN, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Cold chain logistics is one of the fastest-growing industries in the world, projected to top $420 billion this year alone. That surge comes with rising demand for product, speed, and increasingly, gear that can keep up with the conditions.
Ergodyne is answering that call with its rapidly expanding cold storage collection. The worksite safety pioneer just launched its warmest freezer jacket to date, new thermal impact gloves, and merino blend socks—rounding out a head-to-toe system for cold storage and sub-zero work.
'We've built this collection directly with the folks who do it, day in and day out,' said Ergodyne Product Manager, Claudia Weber. Weber credits the quick adaption by major players in the cold chain space to her team's relentless focus on what crews really need. 'I think it's resonating because they know it was not only made for them (the workers), but with them, too.'
Field testing with real cold storage teams, ongoing feedback loops, and on-site observations ensure every feature is grounded in real-world utility. An easy to miss but impactful example of this process are the exterior sizing labels found on outer layers, which allows for instant ID off the rack.
'Seems like not a huge deal,' said Weber. 'But to the workers sifting through the gear every day to find the right size, it is.'
But as cold storage PPE demand heats up, so does confusion around one of the most asked questions in the industry: What do temperature ratings actually mean?
"There's a lot of misinformation—and even more misunderstanding—about what temperature ratings truly represent," said Ergodyne President, Greg Schrab. 'We're committed to educating our users and helping them make informed decisions based on the best information available, not assumptions.'
To that end, Ergodyne has published a guide aimed at demystifying temperature ratings, laying out what they measure, how they're tested, and why context—like activity level and duration of exposure—matters just as much as the rating itself. Read the full piece here.
'Just like any PPE, cold storage crews need the proper information about their thermal gear to make the right choice for their application,' Schrab continued. 'That's why we've always been as serious about education as we are about innovation.'
For more information on the latest in Ergodyne's cold storage collection, visit ergodyne.com.
ABOUT ERGODYNE
Since 1983, Tenacious Holdings, Inc. (dba Ergodyne, a Klein Tools Company) has pioneered the development of products that Make The Workplace A Betterplace™. What started with just one product has grown into a line of top flight, battle-tested, Tenacious Work Gear®; all precision crafted to provide protection, promote prevention and manage the elements for workers on jobsites the world over. The current lineup is extensive and constantly growing: ProFlex® Hand Protection, ProFlex® Knee Pads, ProFlex® Supports, Skullerz® Head & Face Protection, Skullerz® Eye Protection, Trex® Traction, KREW'D® Skin Protection, Chill-Its® Cooling Products, N-Ferno® Warming Products, GloWear® Hi-Vis Apparel, Squids® Lanyards, Arsenal® Gear and Tool Storage, and SHAX® Portable Work Shelters.
Originally posted on: www.ergodyne.com
Attachment
New Cold Storage Gear Solutions
CONTACT: Ergodyne 8002258238 tenaciousnation@ergodyne.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
31 minutes ago
- Business Wire
SWBC Mortgage Honored with 2025 Home Possible RISE Awards® for Fastest Growth by Freddie Mac
SAN ANTONIO--(BUSINESS WIRE)--SWBC Mortgage Corporation is proud to announce that it has been named a 2025 Home Possible RISE Awards® winner by Freddie Mac in the prestigious 'Fastest Growth' category for Regional Independent Mortgage Bankers. We remain committed to helping families across the country achieve the dream of homeownership through innovative, accessible, and sustainable lending solutions. The annual program, Recognizing Individuals for Sustained Excellence (RISE) Awards, celebrates top sellers across multiple categories for excellence with Freddie Mac Home Possible® and Housing Finance Agency (HFA) Advantage® mortgages—affordable lending solutions expanding access to low- to moderate-income borrowers. This recognition, awarded in May 2025, underscores SWBC Mortgage's strong dedication to expanding homeownership opportunities and addressing affordability challenges through innovative and responsible lending solutions. The company earned this distinction based on its significant loan volume growth between the first and second half of 2024. 'We are honored to receive this award from Freddie Mac. This recognition is a testament to the hard work and dedication of our entire team,' said Kerry Dannenberg, President of SWBC Mortgage. 'We remain committed to helping families across the country achieve the dream of homeownership through innovative, accessible, and sustainable lending solutions.' For more information about SWBC Mortgage and its lending programs, visit our website. About SWBC Mortgage Corporation SWBC Mortgage Corporation, a wholly owned subsidiary of SWBC, is a full-service mortgage lender approved by FNMA, FHLMC, and GNMA. Headquartered in San Antonio, Texas, SWBC Mortgage has been providing mortgage banking services since 1988. Through the changing landscape of the mortgage industry, the company has remained committed to service, integrity, and stability while growing to serve communities and borrowers in 44 states + D.C. Today, SWBC Mortgage is consistently recognized as one of the top 50 lenders in America and is home to numerous top-ranked originators. Building on a rich history of success, SWBC Mortgage has highly experienced team members who leverage streamlined digital tools to deliver efficient service and support, while providing a personal, experienced touch to the mortgage process. SWBC Mortgage provides innovative technology and resources built to streamline the mortgage process and provide support from application through servicing. About SWBC As a diversified financial services company, SWBC provides financial institutions, businesses, and individuals with a wide range of insurance, mortgages, wealth management, employee benefits, and more. Headquartered in San Antonio, Texas, SWBC has partners and divisions across all 50 states and Mexico and manages businesses worldwide. No matter how wide its reach, SWBC always listens to our customers' needs, analyzes their current situations, and recommends customized solutions. For more information about our innovative approach to personalized service, visit SWBC's website.
Yahoo
an hour ago
- Yahoo
Bora Pharmaceuticals Announces Multi-Year Expansion for Midwest Manufacturing Site, as Upsher-Smith Entity Split is Finalized
Buildout includes Gerteis Macro-Pactor® install, with additional investments to follow, to meet industry demand at Minnesota facility MAPLE GROVE, Minn., August 05, 2025--(BUSINESS WIRE)--Bora Pharmaceuticals Co., Ltd. ("Bora" or "the Company", TWSE: 6472), a global leader in pharmaceutical manufacturing, has announced plans for significant investments to expand its manufacturing and packaging capabilities at its facility in Maple Grove, Minnesota. This is a major upgrade to the site, which Bora acquired in 2024 as part of its $210 million acquisition of Upsher-Smith Laboratories, expanding its U.S. manufacturing footprint. As the entity separation from Upsher-Smith Laboratories takes effect on August 5, Bora continues its growth amid surging demand for oral solid dose (OSD) development and manufacturing brought on by increasingly complex formulations, novel drug delivery technologies, and the growing shift of biologics into OSD formats. Bora has already secured multiple multi-million-dollar contracts for development and commercial supply of advanced OSD programs. "With pharmaceutical companies relying more heavily on specialized CDMO partners to scale production and maintain quality, top-tier manufacturing capacity and technical expertise are at a premium," said J.D. Mowery, president of Bora's CDMO business. "Bora's Maple Grove facility offers a unique opportunity for innovators to secure space in a state-of-the-art site staffed by experts in formulation development, tech transfer, and commercial manufacturing." The first phase of Bora's investment will add a Gerteis Macro-Pactor® at the company's state-of-the-art site. This investment initiates a broader buildout of 100,000 square feet of dedicated shell space designed to streamline production for partners with high-volume needs. The Gerteis Macro-Pactor® roller compactor will be installed and operational in the third quarter of 2025. "As we complete our transition from Upsher-Smith, we're creating the infrastructure to deliver integrated manufacturing, packaging, and analytical services with the speed and quality our clients need," shared Dennis Hall, Vice President and General Manager of the Maple Grove site. "As we expand our capabilities, we look forward to tapping into all the experience and talent in the area." The facility offers on-site quality control laboratories and a dedicated development team to support product and analytical development as well as innovation. It is an FDA-inspected manufacturing site and meets global health authority requirements, ensuring regulatory compliance. From early development and scale-up to process optimization and commercial manufacturing, Bora's experienced teams support customers at every stage of the product lifecycle. The company's commercial on-time, in-full (OTIF) delivery record is unmatched, reinforcing Bora's role as a trusted partner, supporting clients with secure, consistent supply. For more information, visit About Bora Pharmaceuticals Bora Pharmaceuticals is a premier international contract development and manufacturing organization (CDMO) specializing in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, biologics, and sterile injectable pharmaceutical products. From our world-class sites in North America and Asia, we deliver drug products with unparalleled quality to more than 100 markets around the world. For more information, visit View source version on Contacts Liz Robinsonlrobinson@ 847-702-8099
Yahoo
an hour ago
- Yahoo
Gynecological Devices Market Valuation to Reach US$ 20.19 Billion By 2033
Driven by an aging population and a strong shift toward minimally invasive procedures, the market is dominated by surgical devices and robotics. Hospitals and clinics remain primary end-users, investing heavily in advanced technology despite reimbursement pressures. Chicago, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The global gynecological devices market was valued at US$ 10.18 billion in 2024 and is expected to reach US$ 20.19 billion by 2033, growing at a CAGR of 7.90% during the forecast period 2025–2033. The global gynecological devices market is currently navigating a period of profound and accelerated transformation. This is not a gradual evolution but a dynamic surge, creating a landscape rich with opportunity for manufacturers, investors, and healthcare systems worldwide. A confluence of powerful drivers—including an unprecedented influx of venture capital into women's health technology, the escalating prevalence of complex gynecological conditions, and a wave of disruptive technological advancements—is fueling this robust growth. The market is moving beyond incremental improvements toward fundamental shifts in diagnostics and therapeutics. Free Report Sample Available for Immediate Download: An exhaustive analysis of data reveals a compelling, multi-layered narrative of expansion. This in-depth market research report dissects nine critical segments, presenting meticulously researched, data-driven insights that collectively illuminate the immense and multifaceted opportunities materializing across the global gynecological devices market. Key Finding in Gynecological Devices Market Market Forecast (2033) US$ 20.19 billion CAGR 7.90% Largest Region (2024) North America (42%) By Product Surgical Devices (53.0%) By End Users Hospitals & Clinics (65.26%) Top Drivers Rapidly aging female population creates a growing patient base. Government initiatives are increasingly focused on promoting women's health. High adoption of advanced and innovative medical technologies. Top Trends Rising physician preference for minimally invasive surgical techniques. Growing use of robotic-assisted surgery for gynecological procedures. Increased focus on early diagnostics with advanced imaging systems. Top Challenges Strict and lengthy regulatory approval cycles for new devices. Declining national birth rate impacting obstetrics device demand. Stringent reimbursement policies and pressure on healthcare cost containment. Venture Capital Investment Ignites a Firestorm of Femtech and Gynecological Device Innovation The financial landscape for women's health has been transformed by a massive surge of venture capital, directly spurring innovation and growth in the gynecological devices market. Funding for femtech startups has exceeded US$5 billion since 2020, with US$1.2 billion deployed in 2024 alone. Broadening the view to all women's health startups brings the 2024 total to US$2.6 billion, and, including all women-centric conditions, investment in the US and Europe reached nearly US$10.6 billion in 2024. This is a truly global trend. In Europe, €339.4 million was invested across 47 femtech deals in 2024, and European femtechs had already attracted over €334 million in venture capital by March 2025. This capital empowers companies to launch breakthrough products, fueling a new wave of innovation. Recent examples include Future Family securing a US$400 million financing program in April 2025 and ByHeart raising US$72 million the same month for manufacturing expansion. Significant 2025 investments underscore the diversity of innovation: Gesynta Pharma (US$29 million) and Conceivable Life Sciences (US$18 million) are advancing novel treatments, while Delfina (US$17 million), Twentyeight Health (US$10 million), and Teal Health (US$10 million) highlight the growing impact of AI-powered maternal health and accessible care. The funding cascade continues with Kegg (US$6.5 million), Egal (US$4 million), Fizimed (€4 million), Ema (US$3 million), Trellis Health (US$1.8 million), Raaz (US$1 million), Calla Lily (£1 million), Mabel (€600,000), Femble (€350,000), and AuraFem Health (US$200,000). The UNICEF Venture Fund further nurtures innovation, offering up to US$100,000 in equity-free funding for emerging economies, ensuring support at every level. Addressing Uterine Fibroids Creates a Significant and Highly Costly Market Opportunity Uterine fibroids represent a highly prevalent and economically significant condition, creating a vast and sustained demand for effective therapeutic solutions within the gynecological devices market. The sheer scale of this public health issue is immense. As of 2024, the estimated annual economic cost of uterine fibroids in the United States has escalated to an astonishing US$41.4 billion. A major component of this economic burden is productivity loss, with an estimated US$17.2 billion lost annually in the U.S. due to missed work and short-term disability. The patient population itself is expanding, with data showing that the number of women in the U.S. diagnosed with uterine fibroids increased by 10.6% between 2010 and 2022. This steady growth signals a consistently expanding patient base requiring treatment. The high out-of-pocket cost of traditional surgical interventions further amplifies the market need for innovative, less invasive, and more cost-effective devices. Without insurance coverage, a myomectomy procedure can cost between US$11,000 and US$22,000, while a full hysterectomy ranges from US$9,600 to US$24,000. Alternative, device-centric treatments also carry substantial price tags, with uterine artery embolization costing between US$10,000 and US$15,000, and radiofrequency ablation ranging from US$8,900 to US$20,000. These costs exhibit significant geographic variability; for instance, a laparoscopic hysterectomy could cost approximately US$28,000 in Cleveland, Ohio, while the same procedure in Atlanta, Georgia, might be closer to US$19,000. This cost-prohibitive environment creates a powerful incentive for the adoption of new technologies in the gynecological devices market that can offer superior outcomes at a lower total cost of care. Assisted Reproductive Technology Forges a Burgeoning and Profitable Niche Device Market The increasing societal demand for fertility assistance, driven by trends such as delayed parenthood and rising infertility rates, is a potent force shaping a specialized and highly profitable segment of the gynecological devices market. The global demand for these services is immense, with approximately 2.5 million In-Vitro Fertilization (IVF) cycles now being performed annually across the world. This trend is particularly pronounced in the United States, where the number of IVF cycles performed in SART (Society for Assisted Reproductive Technology) member clinics surged from 389,993 in 2022 to 432,641 in 2023. These procedures directly resulted in the birth of 95,860 babies in the U.S. in 2023. Comprehensive data from 2021 shows that 238,126 patients in the U.S. initiated a total of 413,776 ART cycles, demonstrating the high volume of procedures. The financial investment from patients is substantial and directly fuels demand for the sophisticated equipment, consumables, and diagnostic tools used in these delicate procedures. The average cost of a single IVF cycle in the U.S. ranges from US$12,000 to US$17,000, with some reports from the Department of Health and Human Services placing the potential cost between US$15,000 and US$20,000. This sustained, high-value patient expenditure ensures a robust and growing revenue stream for manufacturers of the specialized instruments essential to modern fertility treatment, making it a cornerstone of the modern gynecological devices market. Robotic Surgery Revolutionizes Gynecological Procedures and Propels Advanced System Device Adoption Minimally invasive robotic surgery has become the gold standard for many gynecological procedures, offering greater precision, shorter recovery times, and improved patient outcomes. This shift is driving rapid adoption of advanced robotic surgical systems, with the da Vinci system leading the market. In 2024 alone, 2,683,000 procedures were performed globally using da Vinci systems, reflecting exponential usage growth. Hardware sales surged as well, with 493 da Vinci surgical systems placed in healthcare facilities in Q4 2024, bringing full-year placements to 1,526. This expansion resulted in substantial financial gains: Intuitive Surgical reported US$2.41 billion in revenue for Q4 2024, up 25% from the previous year. Recurring revenue in the gynecological devices market from proprietary instruments and accessories climbed to US$1.41 billion in Q4, while capital sales of the systems hit US$1.97 billion for the full year. The da Vinci system generally sells for US$0.7 million to US$3.1 million, signifying significant capital commitment from hospitals. By 2020, over 5,500 da Vinci systems were installed in U.S. hospitals, with more than 2,000 hospitals nationwide now utilizing robotic surgery systems. This robust infrastructure supports continued growth: the global gynecological surgery robot market reached approximately US$3.2 billion in 2024 and is poised for further expansion. The outlook is especially strong given that nearly 600,000 hysterectomies are performed in the U.S. every year, many ideal for robotic assistance. Rising Prevalence of Pelvic and Endometrial Disorders Spurs Urgent Device Innovation A growing awareness among both patients and clinicians regarding the diagnosis and treatment of widespread yet historically underdiagnosed conditions such as endometriosis and pelvic organ prolapse (POP) is opening new frontiers for the gynecological devices market. The addressable patient population is substantial and expanding. Projections indicate that the number of American women suffering from at least one pelvic floor disorder is set to increase to 43.8 million by the year 2050. More specifically, the number of women with POP in the U.S. is expected to climb to 4.9 million by 2050, while the global population of POP patients is projected to reach an enormous 156 million by 2036. For endometriosis, a condition infamous for its diagnostic challenges, the average time from symptom onset to a definitive diagnosis is currently a staggering 8 years and 10 months. This diagnostic delay represents a critical unmet need and a clear opportunity for innovative diagnostic devices. Promising clinical research is underway to address these therapeutic gaps. A clinical trial involving 36 participants is evaluating a cannabidiol extract for endometriosis pain and is expected to conclude in December 2024, while another larger pain reduction trial with 102 participants is set to conclude in August 2024. Success in these trials could pave the way for new treatment paradigms supported by new devices. At-Home Testing Empowers Consumers and Rapidly Expands the Diagnostic Device Market A fundamental paradigm shift toward patient-centric care, emphasizing convenience, privacy, and empowerment, is fueling explosive growth in the at-home testing sector. This consumer-driven movement represents a critical expansion corridor for the diagnostic segment of the gynecological devices market. The market size reflects this rapid adoption; the global at-home testing market is estimated to reach a value of US$7,789.1 million in 2025, a healthy increase from its US$7,432.3 million valuation in 2024. The fertility testing sub-market is a particularly strong contributor to this growth, and it is estimated to be valued at US$672.9 million in 2025. Long-term projections are even more bullish, with the global Ovulation Test Market projected to expand to US$4.04 billion by 2032. Similarly, the broader global Fertility Testing Devices Market, which was valued at US$702.59 million in 2023, is projected to surge to an impressive US$1,171.55 million by 2032. The distribution channels for these devices are also modernizing to meet consumer demand. The online pharmacy segment has emerged as the dominant channel, holding the largest share of the fertility testing devices market in 2023 at 41.12%. This trend opens up a powerful direct-to-consumer channel, reshaping marketing and logistics for the entire gynecological devices market. Core Surgical and Diagnostic Device Advancements Enhance Overall Patient Care Efficacy Relentless and continuous innovation in the design and function of core surgical and diagnostic instruments remains a fundamental pillar of growth for the gynecological devices market. These advancements directly translate into improved clinical efficacy, enhanced safety profiles, and better patient experiences. A landmark development occurred in 2025 when Kephera Diagnostics launched its EndomTest, which stands as the first commercially available non-invasive blood test for endometriosis in the United States. This represents a significant leap forward in diagnostics. Simultaneously, the regulatory environment is adapting to support and safeguard this innovation. In November 2024, the Food and Drug Administration (FDA) announced a new communications pilot program specifically designed to enhance the medical device recall process, a program that explicitly includes obstetrics and gynecology devices. This heightened focus on safety is critical, as evidenced by an April 2024 recall of Boston Scientific's Obsidio Embolic device. A comprehensive review of high-risk recalls from 2002 through 2016 identified 7 distinct class I recall events that affected over 88,000 women's health medical devices. This history informs the current proactive regulatory stance, which ultimately fosters greater trust and ensures the long-term, sustainable health of the gynecological devices market. Tailor This Report to Your Specific Business Needs: The Staggering Economic Burden of Gynecological Conditions Underscores Urgent Device Need The immense economic weight imposed by common gynecological conditions on healthcare systems, employers, and patients provides a powerful and persuasive argument for the value proposition of effective and cost-efficient medical devices. The annual economic burden of uterine fibroids in the U.S. is a clear example, estimated to be as high as US$41.4 billion. A major driver of this staggering cost is the impact on workforce productivity, with lost wages due to fibroids costing American women approximately US$17.2 billion every year. The economic drain extends beyond fibroids. The annual surgical costs in the U.S. for treating pelvic organ prolapse now exceed US$1.523 billion. These multi-billion-dollar figures create a compelling business case for payers and healthcare providers to aggressively invest in advanced gynecological devices. Devices that can reduce the need for expensive surgeries, shorten hospital stays, minimize recovery times, and mitigate long-term complications offer a clear and quantifiable return on investment. This powerful economic reality serves as a persistent and significant demand driver for the entire gynecological devices market. Global Gynecological Devices Market Major Players: Karl Storz SE & Co. KG Hologic Inc. Boston Scientific Corporation B. Braun Melsungen AG Becton, Dickinson and Company CONMED Corporation CooperSurgical Inc. Coloplast A/S Johnson & Johnson (Ethicon) Medtronic plc Olympus Corporation Stryker Corporation Richard Wolf GmbH Intuitive Surgical Teleflex Incorporated Minerva Surgical Inc. Lumenis Ltd. Other Prominent Players Market Segmentation: By Product Surgical Devices Gynecological Imaging Devices Portable Tools By End Use Hospital & Clinics Ambulatory Surgery Centers (ASCs) By Region North America Europe Asia Pacific Middle East Africa South America Explore the Report Before You Buy – Book a Walkthrough: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website:
